Skip to main content
OpenTrials

Clinical trial condition

Triple Negative Breast Cancer

Explore clinical trials studying Triple Negative Breast Cancer. Study availability and eligibility vary by location and protocol.

294 public trials 113 recruiting studies
Refine in advanced search Browse all conditions

Triple Negative Breast Cancer trial results

Completed

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +35 more
Locations
  • Mayo Clinic Scottsdale, Arizona, United States
  • HonorHealth Scottsdale, Arizona, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details
Completed

Emotions Immunology and Breast Cancer

NCT03609671

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +8 more
Locations
  • Houston Methodist Hospital Cancer Center Houston, Texas, United States
  • Houston Methodist Hospital Houston, Texas, United States
View Trial Details
Completed

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

NCT02580448

Conditions
Advanced Breast Cancer, Breast Cancer, Breast Diseases, +12 more
Locations
  • Wallace Tumor Institute- University of Alabama Birmingham, Alabama, United States
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • University of Colorado Aurora, Colorado, United States
  • Rocky Mountain Cancer Centers Lakewood, Colorado, United States
View all 36 locations
View Trial Details
Completed

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

NCT02225470

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +9 more
Locations
  • 04 Eisai Trial Site Bengbu, Anhui, China
  • 37 Eisai Trial Site Hefei, Anhui, China
  • 01 Eisai Trial Site Beijing, Beijing Municipality, China
  • 03 Eisai Trial Site Beijing, Beijing Municipality, China
View all 35 locations
View Trial Details
Completed

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

NCT01520389

Conditions
Advanced Solid Tumors, Breast Diseases, Breast Neoplasms, +27 more
Locations
  • University of Colorado Denver Aurora, Colorado, United States
  • Horizon Oncology Research, Inc. Lafayette, Indiana, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • South Texas Accelerated Research Therapeutics, LLC (START) San Antonio, Texas, United States
View Trial Details

Related conditions